Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01851850

Enrollment

Registered

2013-05-13

Start date

2013-05-31

Completion date

2016-05-24

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

PD, Off periods, quality of life, dyskinesia, end-off-dose motor fluctuations

Brief summary

The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.

Interventions

DRUGOpicapone

25mg or 50mg once per day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* clinical diagnosis with PD * subjects who are willing to participate in the trial. * subjects who participated in the BIA 9-1067-302 clinical trial.

Exclusion criteria

* subjects who didn't take part at the BIA 9-1067-302 clinical trial.

Design outcomes

Primary

Measure	Time frame	Description
off periods	6 month	number of off periods during the day without worsening dyskinesia.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026